Elder Pharmaceuticals Ltd. - Research Center
532322 ELDERPHARM Group (Z) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Jun ' 14 | Jun ' 13 | Mar ' 13 | Mar ' 12 | Mar ' 11 | |
|---|---|---|---|---|---|
| Sales | 483.47 | 1,233.10 | 1,043.85 | 982.64 | 827.16 |
| Operating profit | -88.10 | 269.07 | 211.18 | 210.07 | 176.16 |
| Interest | 260.06 | 137.97 | 94.32 | 77.89 | 62.00 |
| Gross profit | -333.03 | 157.31 | 143.24 | 140.67 | 120.03 |
| EPS (Rs) | 8.37 | 45.64 | 42.34 | 41.70 | 34.71 |
Annual
results in details
| Jun ' 14 | Jun ' 13 | Mar ' 13 | Mar ' 12 | Mar ' 11 | |
|---|---|---|---|---|---|
| Other income | 15.13 | 26.22 | 26.38 | 8.49 | 5.86 |
| Stock adjustment | 127.68 | 57.16 | 24.43 | -36.99 | -34.07 |
| Raw material | 48.84 | 122.47 | 109.59 | 115.53 | 119.32 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 116.39 | 157.49 | 126.08 | 118.99 | 105.51 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 278.66 | 626.91 | 572.56 | 575.04 | 460.23 |
| Provisions made | - | - | - | - | - |
| Depreciation | 29.16 | 36.52 | 29.19 | 27.15 | 27.25 |
| Taxation | 0.67 | 21.97 | 22.00 | 21.59 | 16.50 |
| Net profit / loss | 17.18 | 93.74 | 86.96 | 85.64 | 71.29 |
| Extra ordinary item | 380.04 | -5.09 | -5.09 | -6.29 | -4.99 |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 20.54 | 20.54 | 20.54 | 20.54 | 20.54 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | 153.49 | 134.72 | 123.24 | 124.05 | 126.38 |
| Agg.of non promotoholding (%) | 74.74 | 65.60 | 60.01 | 60.40 | 61.54 |
| OPM (%) | -18.22 | 21.82 | 20.23 | 21.38 | 21.30 |
| GPM (%) | -66.79 | 12.49 | 13.38 | 14.19 | 14.41 |
| NPM (%) | 3.45 | 7.44 | 8.13 | 8.64 | 8.56 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis